All case studies
Case studyASX:NUZ

How Neurizon raised $17.8m by directly engaging 20% of their shareholder base.

Dr Michael Thurn (CEO) maximised investor attention and demand throughout a capital raise.

Industry
Biotechnology
01

Problem

Companies struggle to identify and capitalise on latent investor demand during a raise.

02

Impact

Neurizon raised $17.8m in total, with $7.8m via a heavily oversubscribed SPP (3.9x the original target) and 20% of the register participating.

9 months
With InvestorHub
$17.8m
Capital raised
3.9x
More capital than target
8.3k
Unique investors engaged
20% of our share registry participated in the capital raise. The $17.8m we've raised gives us the funding and confidence to pursue our objectives.
DMDr Michael ThurnCEO, Neurizon Therapeutics (ASX:NUZ)

Take control of your register

See how InvestorHub helps listed companies close the distance to their shareholders.